CTL102/CB1954 was originally developed for treating solid tumors. Phase I clinical trials were completed for a range of cancers, including prostate cancer and liver cancer. Consequently a great deal of human data was collected prior to application of the technology in the orthopaedic space.

The 12 subject clinical trial in elderly patients suffering from debilitating levels of aseptic loosening demonstrated that GDEPT therapy followed by cement injection is a potentially safe and feasible alternative to revision surgery, particularly in patients who cannot undergo surgery. The observed improvements in mobility and reduction in pain warrants further clinical trial work.

Whilst the initial trial work was in hips, the CTL102/CB1954 strategy is a platform technology, with potential for application in other joints including knees and shoulders.